European Medicines Agency

MMedication

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

June 26, 2026

The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously…

MMedication

Regeneron (REGN) Says EMA Accepted Review for Otarmeni Application

June 7, 2026

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Debt-Free S&P 500 Stocks to Buy Now. On…

MMedication

Milestone announces acceptance of MAA by EMA for etripamil nasal spray

January 7, 2026

Milestone Pharmaceuticals (MIST) announced the acceptance of a Marketing Authorization Application, MAA, by the European Medicines Agency, EMA,…

MMedication

Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism

December 31, 2025

REDWOOD CITY, Calif., December 31, 2025–(BUSINESS WIRE)–Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery…

MMedication

December 12, 2025

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) said its high-dose version of Wegovy has received a…

Lilly’s Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

Regeneron (REGN) Says EMA Accepted Review for Otarmeni Application

Milestone announces acceptance of MAA by EMA for etripamil nasal spray

Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism

High-Dose Wegovy Takes Aim at Lilly’s Zepbound